Keyword: Affimed Therapeutics

Scott Gottlieb goes back to biotech investing; Seattle Genetics taps first CCO; Affimed parts with CSO; and CSL Behring poaches former Biogen exec.

Affimed has terminated its bispecific T-cell engager program after the FDA hit it with a clinical hold and shifted ts focus to innate cell engagers.

Just a week after Affimed decided to put its T cell engager for blood cancers on hold, the FDA has placed the program on full clinical hold.

Affimed has halted work on trials of its lead T cell engager AFM11 for blood cancers after a death and two life-threatening events.

The deal features $5 billion in milestones and royalties that could land in Affimed’s bank account if the immunotherapies succeed.

Alland landed the role on the strength of a CV that features stints spent at AstraZeneca, Bristol-Myers Squibb and Novartis.

Already partnering with the likes of Adaptimmune and Cellectis for immuno-oncology, MD Anderson has today added Germany’s Affimed to its growing list of I/O players.